Patented-drug sales hit $24.4 billion in Canada; prices barely moved, PMPRB reports
The newly tabled PMPRB report shows patented-medicine sales rose 10.6% in 2025 while the average list-price index increased just 0.1%. Higher-cost treatment choices helped drive the spending increase.
In this article & details
Sales of patented medicines in Canada reached $24.4 billion in 2025, up 10.6% from the previous year, according to the PMPRB annual report tabled November 20. Patented products represented about 48% of medicine sales nationwide.
The increase in spending was much larger than the change in average list prices. The 2025 Annual Report puts the annual increase in its Patented Medicines Price Index at 0.1%, compared with consumer-price inflation of 2.1%. The sales figure measures revenue across the market; the price index tracks changes in the prices of individual patented medicines.
Higher-cost medicines pushed spending upward
The report identifies a shift toward higher-cost patented medicines as an important contributor. That change in the mix of treatments added $1.57 billion, or 7.3%, to expenditures. A market can therefore become more expensive even when the average change in existing products’ list prices is small.
Patented-medicine sales were $22.1 billion in 2024. The 2025 total was approximately $2.3 billion higher, extending a period of rising sales: the report lists $17.4 billion in 2021. The figures describe patented medicines, rather than the entire prescription and non-prescription drug market.
Canadian prices remained high internationally
The PMPRB’s release says Canadian list prices ranked third highest within its 11-country comparison group, behind the United Kingdom and Spain, and seventh among 35 OECD countries. Canada accounted for 2.1% of worldwide pharmaceutical sales and was the eighth-largest national market.
International comparisons in the report use list prices. They do not capture confidential rebates or other indirect discounts available to some payers. The report also cautions that its aggregate pricing analysis does not determine whether an individual medicine would require an in-depth price review or a hearing under the regulator’s guidelines.
Research spending and price oversight
Rights holders reported $1.73 billion in Canadian research and development expenditures for 2025, with an R&D-to-sales ratio of 4.9% under the regulatory reporting definition. The R&D ratio uses a separately defined rights-holder sales base, which differs from the $24.4-billion patented-medicine sales total.
The PMPRB reported 1,086 patented medicines for human use and 82 newly reported dosage forms and strengths. The annual report covers 2025 activity; it was released in November 2026. New staff guidelines, published in June 2025, took effect January 1, 2026. The board’s reporting function tracks market trends, while its price-review work addresses potentially excessive patented-medicine prices.
References
- Federal Minister of Health tables the 2025 Annual Report of the Patented Medicine Prices Review Board — November 20, 2026 — Patented Medicine Prices Review Board
- Annual Report 2025 — Patented Medicine Prices Review Board
Discussion
0 commentsJoin the discussion. Anyone can read the comments. To comment, log in or create a free individual account.
No comments yet.